Gilead Sciences Inc. announced that two Phase 3b switch studies evaluating Odefsey (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) for the treatment of HIV-1 infection met their primary objectives.
Merck said the U.S. Food and Drug Administration has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application for bezlotoxumab, an investigational agent for prevention of Clostridium difficile (C. difficile) infection recurrence.
Healthcare agencies were brought together for the Medical Advertising Hall of Fame’s “View from the Top” leadership forum.
Promotions demonstrate agency commitment to strategic thinking and client-focused delivery excellence July 20, 2016, PHILADELPHIA, Penn. — Razorfish Health, a uniquely integrated health marketing agency, announces the promotion of […]
Merck is globally committed to an antimicrobial stewardship encompassing surveillance, R&D, and health policy.
FDA approval makes Xolair the first available biologic for children ages 6 and up with uncontrolled allergic asthma.
Leading agency named Dreamit’s first branding and marketing partner, with an eye toward boosting success of Dreamit entrepreneurs JULY 6, 2016, NEW YORK AND PHILADELPHIA, PA – Digitas Health […]
Join HBA for this interactive webinar where you will learn how to avoid the three most common career mistakes professional women make when balancing a family.
Every female leader needs to have an authentic, strong leadership voice to ensure success in any conversation. Join HBA for this 12th program in the Career Conversation series.
More patients and companies are increasingly adopting mobile health solutions that have created a highly effective platform for patient engagement.